We at Pharmatech AI are proud to announce that we have secured a $5 million strategic investment from Rollman Management, a renowned investment firm with a focus on groundbreaking technologies. This partnership underscores the confidence in our mission to revolutionize pharmaceutical research through artificial intelligence and blockchain technology.
This investment will enable us to further expand our proprietary AI-MDIP (AI Multi-Drug Interaction Predictor) platform and accelerate our research in pain therapy, cannabinoid research, and nanomedicine. The funds will be allocated to the following key areas:
- Expansion of our AI research infrastructure to accelerate drug discovery processes
- Development of our sustainable research center with advanced laboratory equipment
- Acceleration of B2B SaaS platform development for pharmaceutical partners
- Strengthening of the Pharmatech AI ecosystem and token utility
Our CEO commented: “This partnership with Rollman Management marks a significant milestone for our company. The investment not only validates our innovative approach to pharmaceutical research but also enables us to scale our technology faster and develop life-changing therapies.“
This investment comes at a time when Pharmatech AI has made significant progress in developing its AI-powered platform and is preparing to launch its B2B SaaS offering for pharmaceutical companies.
About Pharmatech AI
Pharmatech AI is an innovative research company using a proprietary AI platform to accelerate and reduce the cost of developing new drug combinations. We focus on high-potential areas including Pain Therapy, Natural Product Research (Cannabinoids), and Nanomedicine.